Hunt Nimrata, Executive Vice President at IDXX (Idexx Laboratories), has demonstrated a consistent pattern of selling activity in the company’s stock over the past year, with no recent purchases recorded. Since August 2025, Nimrata has executed 10 sales totaling approximately $15.8 million, significantly outweighing cumulative buys of $7.5 million. The most recent transactions include a $1.12 million sale on March 3, 2026, and a $1.78 million sale on February 26, 2026, following earlier disposals in November 2025 and August 2025. Notably, the November 2025 sales were particularly substantial, with four transactions exceeding $3.59 million in aggregate value, alongside derivative dispositions coded as "M" (merger or acquisition-related) totaling over $4.8 million.
The filings also reveal multiple smaller sales in August 2025, including a $787,840 transaction on August 11 and three sales on August 6 totaling $4.5 million. While some filings from February 2026 show derivative transactions coded as "A" (award or grant) and "F" (payment of exercise price or tax liability), these did not involve monetary value. Nimrata’s trading activity is exclusively concentrated in IDXX, with no diversification across other securities. The absence of recent buys and the sustained selling trend suggest a directional bias toward reducing exposure, though the reasons remain undisclosed in regulatory filings.
AI-assisted summary